These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 11727523)

  • 1. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials.
    Kirn D
    Expert Opin Biol Ther; 2001 May; 1(3):525-38. PubMed ID: 11727523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned?
    Kirn D
    Gene Ther; 2001 Jan; 8(2):89-98. PubMed ID: 11313778
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial.
    Reid T; Galanis E; Abbruzzese J; Sze D; Andrews J; Romel L; Hatfield M; Rubin J; Kirn D
    Gene Ther; 2001 Nov; 8(21):1618-26. PubMed ID: 11895000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intravascular adenoviral agents in cancer patients: lessons from clinical trials.
    Reid T; Warren R; Kirn D
    Cancer Gene Ther; 2002 Dec; 9(12):979-86. PubMed ID: 12522437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
    Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
    Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer.
    Vasey PA; Shulman LN; Campos S; Davis J; Gore M; Johnston S; Kirn DH; O'Neill V; Siddiqui N; Seiden MV; Kaye SB
    J Clin Oncol; 2002 Mar; 20(6):1562-9. PubMed ID: 11896105
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of a replication-selective adenovirus against ovarian carcinomatosis is dependent on tumor burden, viral replication and p53 status.
    Heise C; Ganly I; Kim YT; Sampson-Johannes A; Brown R; Kirn D
    Gene Ther; 2000 Nov; 7(22):1925-9. PubMed ID: 11127580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity.
    Nemunaitis J; Cunningham C; Buchanan A; Blackburn A; Edelman G; Maples P; Netto G; Tong A; Randlev B; Olson S; Kirn D
    Gene Ther; 2001 May; 8(10):746-59. PubMed ID: 11420638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints.
    Reid T; Galanis E; Abbruzzese J; Sze D; Wein LM; Andrews J; Randlev B; Heise C; Uprichard M; Hatfield M; Rome L; Rubin J; Kirn D
    Cancer Res; 2002 Nov; 62(21):6070-9. PubMed ID: 12414631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous administration of ONYX-015, a selectively replicating adenovirus, induces antitumoral efficacy.
    Heise CC; Williams AM; Xue S; Propst M; Kirn DH
    Cancer Res; 1999 Jun; 59(11):2623-8. PubMed ID: 10363984
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenovirus vectors for gene therapy, vaccination and cancer gene therapy.
    Wold WS; Toth K
    Curr Gene Ther; 2013 Dec; 13(6):421-33. PubMed ID: 24279313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ONYX-015: mechanisms of action and clinical potential of a replication-selective adenovirus.
    Ries S; Korn WM
    Br J Cancer; 2002 Jan; 86(1):5-11. PubMed ID: 11857003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.
    Nemunaitis J; Ganly I; Khuri F; Arseneau J; Kuhn J; McCarty T; Landers S; Maples P; Romel L; Randlev B; Reid T; Kaye S; Kirn D
    Cancer Res; 2000 Nov; 60(22):6359-66. PubMed ID: 11103798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial.
    Mulvihill S; Warren R; Venook A; Adler A; Randlev B; Heise C; Kirn D
    Gene Ther; 2001 Feb; 8(4):308-15. PubMed ID: 11313805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency.
    Liu TC; Hallden G; Wang Y; Brooks G; Francis J; Lemoine N; Kirn D
    Mol Ther; 2004 Jun; 9(6):786-803. PubMed ID: 15194046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replicating adenoviruses in cancer therapy.
    Dobbelstein M
    Curr Top Microbiol Immunol; 2004; 273():291-334. PubMed ID: 14674605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic Replication of E1b-Deleted Adenoviruses.
    Cheng PH; Wechman SL; McMasters KM; Zhou HS
    Viruses; 2015 Nov; 7(11):5767-79. PubMed ID: 26561828
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the replication of adenoviral gene therapy vectors to lung cancer cells: the importance of the adenoviral E1b-55kD gene.
    Hay JG; Shapiro N; Sauthoff H; Heitner S; Phupakdi W; Rom WN
    Hum Gene Ther; 1999 Mar; 10(4):579-90. PubMed ID: 10094201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials with oncolytic adenovirus in China.
    Yu W; Fang H
    Curr Cancer Drug Targets; 2007 Mar; 7(2):141-8. PubMed ID: 17346105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.